Refining Liquid Biopsy: Generating More Information From Cell Free DNA
Liquid biopsy for profiling of cell free DNA (cfDNA) in blood holds huge promise to transform how we experience and manage cancer by early detection and identification of residual disease and subtype. However, a standard blood draw yields an average of only 10 ng of cfDNA, of which DNA derived from the tumor is a small minority.
Genetic and methylation data together have been shown to be more powerful for the detection of early cancer than either alone. Constrained to measuring four states of information, existing NGS- based technologies sacrifice genetic for methylation calling.
Download this poster to see the latest data illustrating the potential of duet multiomics solution +modC and to learn more about how this 5-letter technology:
- Generates high-quality data from low input DNA samples
- Obtains more sensitive somatic variant calling through error suppression at 8 or 12 possible substitution types
- Is able to perform multi-modal information that can be used to discriminate cancer patients from healthy controls